Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Q3 net loss widens to $21.5 million from $11.8 million

Negative Impact 3 of 5 earnings

Trevi Therapeutics reported a third-quarter 2026 net loss of $21.5 million, or $0.13 per share, up from $11.8 million, or $0.08 per share, a year earlier, as research and development expenses rose to $19.1 million from $10.1 million. The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities and said this funds cash runway into 2030, which matters to shareholders because spending is rising and the filing shows no revenue line.

Key points

  • Net loss of $21.5 million for the quarter ended September 30, 2026, versus $11.8 million in the same period of 2025
  • Research and development expenses of $19.1 million, up from $10.1 million, driven by Phase 3 OCEAN-1 and OCEAN-2 and Phase 2b LAKE trials
  • Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026; the company expects cash runway into 2030
  • Positive FDA meeting in October 2026 on the non-IPF ILD program; Phase 2 dose-ranging trial expected to start in the first quarter of 2027

The filing

CompanyTrevi Therapeutics, Inc. (TRVI)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:26 PM ET
Accession number0001193125-26-453670

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 4:36 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.